Stock on Trader’s Radar: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) share price soared 10.49% or 10.38 points to reach at $109.30 during previous trading session. The stock’s price fluctuated within the range of $98.92 – $113.04 during previous trading session. A total of 7.67M shares exchanged hands, whereas the company’s average trading volume stands at 1.62M shares. Edwards Lifesciences Corp (NYSE:EW) has a market capitalization of $23.31B and most recently 211.60M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Edwards Lifesciences Corp (NYSE:EW) is at 82.56.

According to sentiments of 19 analysts the mean estimates of short term price target for the company’s stock is marked at $116.11. The most optimistic analyst sees the stock reaching $140 while the most conventional predicts the target price at $80.

The consensus mean EPS for the current quarter is at $0.82 derived from a total of 20 estimates. According to analysts minimum EPS for the current quarter is expected at $0.79 and can go high up to $0.86. However a year ago during same quarter Edwards Lifesciences Corp (NYSE:EW) reported $0.71 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $0.87 per share according to consensus of 20 analysts.

According to sentiments of 18 analysts the company is expected to report revenues of $777.83M for the current quarter. Bearish revenue estimates established at $760M while the bullish revenue forecast has been figured out at $793M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.95 on the shares of Edwards Lifesciences Corp (NYSE:EW). Out of rating recommendations 8 have given the stock a Buy while 8 recommend the stock as Outperform. 4 have given the stock a Hold rating, 0 as Underperform and 1 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Edwards Lifesciences Corp (NYSE:EW)’s distance from 20 day simple moving average is 14.96% whereas its distance from 50 day simple moving average is 16.64% along with 8.26% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Edwards Lifesciences Corp (NYSE:EW) shares were trading -10.23% below from the 52-week high mark of $121.75 and +34.74% above from the 52-week bottom of $81.12. The stock hit its 52-week high price on 10/10/16 and 52-week low price on 12/01/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 13.04% in the past one week and climbed 14.01% during previous one month drive, the stock went up 13.70% during past quarter. In the last six months the stock’s performance fell -6.61% while yearly performance of the company advanced 0.42%. The company’s year to date (YTD) performance is at 16.65%.

While taking a glance at financials, we can look at a number of key indicators. Edwards Lifesciences Corp (NYSE:EW) has a Return on Assets (ROA) of 13.60%. The company currently has a Return on Equity (ROE) of 22.60% and a Return on Investment (ROI) of 16.50%. Average true range (ATR-14) of the company sets at 2.59, along with its weekly and monthly volatility of 2.52%, 1.83% respectively. Beta value of the stock stands at 0.66.

The company’s price to free cash flow for trailing twelve months is 47.94. Its quick ratio for most recent quarter is 3.50 along with current ratio for most recent quarter of 4.20. Total debt to equity ratio of the company for most recent quarter is 0.31 whereas long term debt to equity ratio for most recent quarter is 0.31.

Analytical Approach on: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) soared 2.04% during previous trade, a total of 1.64M shares exchanged hands compared with its average trading volume of 1.73M shares whereas its relative volume is 0.75. The stock has a market capitalization of $20.22B along with 211.19M outstanding shares. Stock’s intraday price range hit the peak level of $97.10 and touched the lowest level of $95.37.

Most recently Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 3/31/17 and according to 19 analysts stock’s price will reach at $116.11 during 52 weeks with standard deviation of 10.85. Stock’s minimum price target estimates has been figured out at $80 while the maximum price target forecast is established at $140, if we look at the price target with an optimistic approach it has upside potential of 45% from its latest closing price of $96.69.

Historically, if we look at price target revisions, three weeks ago Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 3/23/17 by the analysts, however the bullish price estimates of the stock set at $140 while the bearish estimates kept at $100 over the next one year. Stock’s 52-week target was retained at $118.13, the estimates indicates a standard deviation of 10.85.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.59. ABR value is precisely based on brokerage recommendations, where out of 16 brokerage recommendations 10 rate Edwards Lifesciences Corp (NYSE:EW) stock a Strong Buy, 2 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 2/2/17 the stock of Edwards Lifesciences Corp (NYSE:EW) downgraded by Leerink Partners from Outperform to Mkt Perform. However previously on 1/3/17 it was upgraded by Guggenheim from Neutral to Buy. A research note issued on 11/8/16 the stock was upgraded by Northland Capital from Market Perform to Outperform.

Edwards Lifesciences Corp (NYSE:EW) performance over the past one year plunged -8.85% whereas its year to date (YTD) performance indicated a bullish trend of 3.19%. During the last six months the stock slipped -16.32%. Quarterly performance of the company shows optimistic momentum of 0.94% while its last one month trend is positive with 2.77%. Stock’s weekly performance expressed up trend of 3.30%.

The company’s price sits 4.01% above from its 50-day moving average of $93.61 and -4.33% below from the stock’s 200-day moving average which is $95.46. Edwards Lifesciences Corp (NYSE:EW)’s shares are currently trading -20.58% away from the 52-week high price of $121.75 and +19.19% far from the 52-week low price of $81.12.

According to consensus agreement of 20 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.82 in their quarterly report and it is expected to announce the company’s results on 4/25/17 After Market Close. For the current quarter the company has high EPS estimates of $0.86 in contradiction of low EPS estimates of $0.79. However a year ago for the same quarter the company has reported $0.71 EPS. Current year EPS projections for Edwards Lifesciences Corp (NYSE:EW) set at $3.41 according to the sentiments of 21 analysts, while its lowest earnings estimates are $3.32 and highest earnings estimates are $3.6.

According to 18 analysts, Edwards Lifesciences Corp (NYSE:EW)’s revenue estimates for the current quarter are $777.83M meanwhile the company has high revenue estimates of $793M in contradiction of low revenue estimates of $760M. For the current year the company’s revenue estimates are $3.26B compared to low analyst estimates of $3.13B and high estimates of $3.38B according to the projection of 21 analysts.

Share Performance and Target Price Review: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) soared 1.20% during previous trade, a total of 4.17M shares exchanged hands compared with its average trading volume of 2.83M shares whereas its relative volume is 1.88. The stock has a market capitalization of $19.55B along with 213.81M outstanding shares. Stock’s intraday price range hit the peak level of $92.98 and touched the lowest level of $89.30.

Most recently Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 12/09/16 and according to 20 analysts stock’s price will reach at $116.22 during 52 weeks with standard deviation of 9.24. Stock’s minimum price target estimates has been figured out at $88 while the maximum price target forecast is established at $140, if we look at the price target with an optimistic approach it has upside potential of 55% from its latest closing price of $90.37.

Historically, if we look at price target revisions, three weeks ago Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 11/15/16 by the analysts, however the bullish price estimates of the stock set at $140 while the bearish estimates kept at $105 over the next one year. Stock’s 52-week target was retained at $124.93, the estimates indicates a standard deviation of 10.94.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.42. ABR value is precisely based on brokerage recommendations, where out of 18 brokerage recommendations 13 rate Edwards Lifesciences Corp (NYSE:EW) stock a Strong Buy, 2 rate the stocks of the company a Buy, 3 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 11/8/16 the stock of Edwards Lifesciences Corp (NYSE:EW) upgraded by Northland Capital from Market Perform to Outperform. However previously on 7/27/16 it was upgraded by BofA/Merrill from Neutral to Buy. A research note issued on 1/21/16 the stock was upgraded by Sun Trust Rbsn Humphrey from Neutral to Buy.

Edwards Lifesciences Corp (NYSE:EW) performance over the past one year soared 10.50% whereas its year to date (YTD) performance indicated a bullish trend of 14.42%. During the last six months the stock slipped -10.64%. Quarterly performance of the company shows declining momentum of -22.24% while its last one month trend is negative with -2.25%. Stock’s weekly performance expressed up trend of 8.42%.

The company’s price sits -9.47% below from its 50-day moving average of $90.10 and -12.42% below from the stock’s 200-day moving average which is $105.45. Edwards Lifesciences Corp (NYSE:EW)’s shares are currently trading -25.77% away from the 52-week high price of $121.75 and +25.17% far from the 52-week low price of $72.20.

According to consensus agreement of 22 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.72 in their quarterly report and it is expected to announce the company’s results on 2/7/17. For the current quarter the company has high EPS estimates of $0.76 in contradiction of low EPS estimates of $0.7. However a year ago for the same quarter the company has reported $0.63 EPS. Current year EPS projections for Edwards Lifesciences Corp (NYSE:EW) set at $2.87 according to the sentiments of 23 analysts, while its lowest earnings estimates are $2.84 and highest earnings estimates are $2.9.

According to 21 analysts, Edwards Lifesciences Corp (NYSE:EW)’s revenue estimates for the current quarter are $764.78M meanwhile the company has high revenue estimates of $789M in contradiction of low revenue estimates of $750M. For the current year the company’s revenue estimates are $2.96B compared to low analyst estimates of $2.94B and high estimates of $2.99B according to the projection of 23 analysts.

Analysts Take on Edwards Lifesciences Corp (NYSE:EW) Share Price History

Edwards Lifesciences Corp (NYSE:EW) plunged -4.66% during previous trade, a total of 4.19M shares exchanged hands compared with its average trading volume of 2.86M shares whereas its relative volume is 2.26. The stock has a market capitalization of $18.22B along with 213.81M outstanding shares. Stock’s intraday price range hit the peak level of $88 and touched the lowest level of $83.42.

Most recently Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 11/15/16 and according to 20 analysts stock’s price will reach at $122.10 during 52 weeks with standard deviation of 10.94. Stock’s minimum price target estimates has been figured out at $88 while the maximum price target forecast is established at $140, if we look at the price target with an optimistic approach it has upside potential of 57% from its latest closing price of $85.04.

Historically, if we look at price target revisions, three weeks ago Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 10/26/16 by the analysts, however the bullish price estimates of the stock set at $140 while the bearish estimates kept at $105 over the next one year. Stock’s 52-week target was retained at $124.93, the estimates indicates a standard deviation of 10.94.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.42. ABR value is precisely based on brokerage recommendations, where out of 18 brokerage recommendations 13 rate Edwards Lifesciences Corp (NYSE:EW) stock a Strong Buy, 2 rate the stocks of the company a Buy, 3 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 11/8/16 the stock of Edwards Lifesciences Corp (NYSE:EW) upgraded by Northland Capital from Market Perform to Outperform. However previously on 7/27/16 it was upgraded by BofA/Merrill from Neutral to Buy. A research note issued on 1/21/16 the stock was upgraded by Sun Trust Rbsn Humphrey from Neutral to Buy.

Edwards Lifesciences Corp (NYSE:EW) performance over the past one year soared 5.61% whereas its year to date (YTD) performance indicated a bullish trend of 7.67%. During the last six months the stock slipped -14.88%. Quarterly performance of the company shows declining momentum of -25.60% while its last one month trend is negative with -27.33%. Stock’s weekly performance expressed down trend of -4.35%.

The company’s price sits -21.20% below from its 50-day moving average of $102.90 and -17.57% below from the stock’s 200-day moving average which is $106.98. Edwards Lifesciences Corp (NYSE:EW)’s shares are currently trading -30.15% away from the 52-week high price of $121.75 and +17.78% far from the 52-week low price of $72.20.

According to consensus agreement of 22 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.74 in their quarterly report and it is expected to announce the company’s results on 2/7/17. For the current quarter the company has high EPS estimates of $0.78 in contradiction of low EPS estimates of $0.71. However a year ago for the same quarter the company has reported $0.63 EPS. Current year EPS projections for Edwards Lifesciences Corp (NYSE:EW) set at $2.88 according to the sentiments of 23 analysts, while its lowest earnings estimates are $2.85 and highest earnings estimates are $2.92.

According to 21 analysts, Edwards Lifesciences Corp (NYSE:EW)’s revenue estimates for the current quarter are $783.85M meanwhile the company has high revenue estimates of $812M in contradiction of low revenue estimates of $766M. For the current year the company’s revenue estimates are $2.98B compared to low analyst estimates of $2.96B and high estimates of $3.01B according to the projection of 22 analysts.

Analyst Outlook on Price Target: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) plunged -3.58% during previous trade, a total of 3.63M shares exchanged hands compared with its average trading volume of 2.31M shares whereas its relative volume is 2.28. The stock has a market capitalization of $17.67B along with 213.81M outstanding shares. Stock’s intraday price range hit the peak level of $92.22 and touched the lowest level of $88.69.

Most recently Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 11/2/16 and according to 20 analysts stock’s price will reach at $122.10 during 52 weeks with standard deviation of 10.94. Stock’s minimum price target estimates has been figured out at $88 while the maximum price target forecast is established at $140, if we look at the price target with an optimistic approach it has upside potential of 58% from its latest closing price of $88.71.

Historically, if we look at price target revisions, three weeks ago Edwards Lifesciences Corp (NYSE:EW)’s price target was revised on 10/5/16 by the analysts, however the bullish price estimates of the stock set at $140 while the bearish estimates kept at $105 over the next one year. Stock’s 52-week target was retained at $126.93, the estimates indicates a standard deviation of 10.01.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.53. ABR value is precisely based on brokerage recommendations, where out of 18 brokerage recommendations 12 rate Edwards Lifesciences Corp (NYSE:EW) stock a Strong Buy, 2 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 7/27/16 the stock of Edwards Lifesciences Corp (NYSE:EW) upgraded by BofA/Merrill from Neutral to Buy. However previously on 1/21/16 it was upgraded by Sun Trust Rbsn Humphrey from Neutral to Buy. A research note issued on 7/13/15 the stock was upgraded by Northland Capital from Market Perform to Outperform.

Edwards Lifesciences Corp (NYSE:EW) performance over the past one year plunged 15% whereas its year to date (YTD) performance indicated a bearish trend of 12.33%. During the last six months the stock slipped -21.48%. Quarterly performance of the company shows declining momentum of -21.48% while its last one month trend is negative with -25.56%. Stock’s weekly performance expressed down trend of -5.88%.

The company’s price sits -22.96% below from its 50-day moving average of $114.17 and -13.37% below from the stock’s 200-day moving average which is $108.70. Edwards Lifesciences Corp (NYSE:EW)’s shares are currently trading -27.14% away from the 52-week high price of $121.75 and +22.87% far from the 52-week low price of $72.20.

According to consensus agreement of 23 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.74 in their quarterly report and it is expected to announce the company’s results on 2/7/17. For the current quarter the company has high EPS estimates of $0.79 in contradiction of low EPS estimates of $0.71. However a year ago for the same quarter the company has reported $0.63 EPS. Current year EPS projections for Edwards Lifesciences Corp (NYSE:EW) set at $2.88 according to the sentiments of 23 analysts, while its lowest earnings estimates are $2.84 and highest earnings estimates are $2.94.

According to 21 analysts, Edwards Lifesciences Corp (NYSE:EW)’s revenue estimates for the current quarter are $786.51M meanwhile the company has high revenue estimates of $812M in contradiction of low revenue estimates of $766M. For the current year the company’s revenue estimates are $2.98B compared to low analyst estimates of $2.94B and high estimates of $3.04B according to the projection of 23 analysts.

Stock Heading Lower: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) share price plunged -17.09% or -19.43 points to reach at $94.25 during previous trading session. The stock’s price fluctuated within the range of $94.25 – $100.86 during previous trading session. A total of 16.80M shares exchanged hands, whereas the company’s average trading volume stands at 1.22M shares. Edwards Lifesciences Corp (NYSE:EW) has a market capitalization of $19.49B and most recently 212.70M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Edwards Lifesciences Corp (NYSE:EW) is at 16.11.

According to sentiments of 20 analysts the mean estimates of short term price target for the company’s stock is marked at $126.83. The most optimistic analyst sees the stock reaching $140 while the most conventional predicts the target price at $94.

The consensus mean EPS for the current quarter is at $0.74 derived from a total of 23 estimates. According to analysts minimum EPS for the current quarter is expected at $0.7 and can go high up to $0.8. However a year ago during same quarter Edwards Lifesciences Corp (NYSE:EW) reported $0.63 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $0.82 per share according to consensus of 13 analysts.

According to sentiments of 21 analysts the company is expected to report revenues of $801.9M for the current quarter. Bearish revenue estimates established at $780.2M while the bullish revenue forecast has been figured out at $841M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.96 on the shares of Edwards Lifesciences Corp (NYSE:EW). Out of rating recommendations 9 have given the stock a Buy while 8 recommend the stock as Outperform. 5 have given the stock a Hold rating, 0 as Underperform and 1 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Edwards Lifesciences Corp (NYSE:EW)’s distance from 20 day simple moving average is -20.43% whereas its distance from 50 day simple moving average is -19.63% along with 7.55% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Edwards Lifesciences Corp (NYSE:EW) shares were trading -22.59% below from the 52-week high mark of $121.75 and +30.54% above from the 52-week bottom of $72.20. The stock hit its 52-week high price on 10/10/16 and 52-week low price on 1/20/16.

When we have a peek on stock’s historical trends we come to know that, the stock has slipped -19.90% in the past one week and plunged -22.25% during previous one month drive, the stock went down -16.59% during past quarter. In the last six months the stock’s performance fell -12.12% while yearly performance of the company advanced 24.85%.The company’s year to date (YTD) performance is at 19.33%.

While taking a glance at financials, we can look at a number of key indicators. Edwards Lifesciences Corp (NYSE:EW) has a Return on Assets (ROA) of 13.30%. The company currently has a Return on Equity (ROE) of 21.80% and a Return on Investment (ROI) of 15.90%. Average true range (ATR-14) of the company sets at 3.33, along with its weekly and monthly volatility of 2.90%, 1.99% respectively. Beta value of the stock stands at 0.62.

The company’s price to free cash flow for trailing twelve months is 46.68. Its quick ratio for most recent quarter is 3.40 along with current ratio for most recent quarter of 4.20. Total debt to equity ratio of the company for most recent quarter is 0.24 whereas long term debt to equity ratio for most recent quarter is 0.24.

Insider Trading and Analyst Recommendations Update: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) exchanged hands1.29M shares versus average trading capacity of 1.31M shares, while its shares’ total market worth is $25.39B along with 212.88M outstanding shares.

The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. For Edwards Lifesciences Corp (NYSE:EW) total 16 number of trades held during last 3 months and 88 during last 12 months, out of them 0 numbers of buys held in last 3 months and 17 buys in last 12 months. Whereas 16 numbers of sells held in last 3 months and 71 sells over the past 12 months.

Insiders has most recently took part in a trading activity, Bobo Donald E JR, CVP, Heart Valve Therapy of the company in a transaction that occurred 9/2/2016 sold 18,000 shares of the stock. The stock was sold at a price of $115.78, for a total value of $2,084,049. Subsequent to the transaction Bobo Donald E JR owned a total of 46,901 shares of the stock.

In a separate transaction on 9/1/2016, Mussallem Michael A, Chairman & CEO sold 4,900 shares of the stock. The stock was sold at a price of $115.66, for a total worth of $566,726. Succeeding to the transaction Mussallem Michael A owned overall 74,838 shares of the stock.

Moreover, Mussallem Michael A, Chairman & CEO sold 44,200 shares of the stock in a reserved transaction that ensued on 9/1/2016. At a price of $115.14, the stock was sold for an entire value of $5,089,020. Consequent to the transaction Mussallem Michael A owned a total of 30,638 shares of the stock.

Currently, 0.30% shares of Edwards Lifesciences Corp (NYSE:EW) are owned by insiders with -49.27% six-month change in the insider ownership. Mussallem Michael A is one of the major insider shareholder of the company’s stock, the insider owns 30,638 shares reported on Aug 11, 2016. Cardis John T is second leading insider shareholder, as of May 13, 2016 the insider owns 98,399 shares of the stock. Verguet Patrick B is another major insider shareholder of the stock, as per record date of Aug 26, 2016 insider owns 128,906 shares of the stock.

Edwards Lifesciences Corp (NYSE:EW) ended last trading session at the price of $117.54 whereas a number of traders indicating mean target price will hit $123.95 over the next twelve months, mean value of price target most recently revised on 08/24/16. Edwards Lifesciences Corp (NYSE:EW)’s highest estimates of price target are $140.00 and low forecast is $94.00 based on the opinion of 20 analysts. The price target estimates represents a standard deviation of 10.13. However brokerage recommendations suggests an ABR of 1.53 based on calls of 16 experts, where 11 brokers polls the stock a Strong Buy, 1 suggest the stock a Buy, 4 suggest Hold, 0 are rating the stock as Sell while 0 as Strong Sell.

Edwards Lifesciences Corp (NYSE:EW) is expected to release the earnings of its current quarter on 10/24/16. The company is expected to release $0.68 EPS during current quarter according to 24 analysts whereas the company reported $0.54 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.64 and high estimate of $0.72. Edwards Lifesciences Corp (NYSE:EW)’s average revenue estimates for the current quarter are $746.62M according to 22 number of analysts. However its lowest revenue estimates are $721.6M and highest revenue estimates are $762M. A year ago the company’s sales were $616.7M. Its yearly sales growth estimates are 21.10%.

Insider Trading and Share Price Activity: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) exchanged hands 1.48M shares versus average trading capacity of 1.35M shares, while its shares’ total market worth is $23.74B along with 212.88M outstanding shares.

The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. For Edwards Lifesciences Corp (NYSE:EW) total 19 number of trades held during last 3 months and 89 during last 12 months, out of them 0 numbers of buys held in last 3 months and 17 buys in last 12 months. Whereas 19 numbers of sells held in last 3 months and 72 sells over the past 12 months.

Insiders has most recently took part in a trading activity, Verguet Patrick B, CVP, Europe of the company in a transaction that occurred 8/24/2016   sold 5,000  shares of the stock. The stock was sold at a price of $116.81, for a total value of $584,032. Subsequent to the transaction Verguet Patrick B owned a total of 128,906 shares of the stock.

In a separate transaction on 8/23/2016, Verguet Patrick B, CVP, Europe sold 10,000 shares of the stock. The stock was sold at a price of $117.54, for a total worth of $1,175,370. Succeeding to the transaction Verguet Patrick B owned overall 128,906 shares of the stock.

Moreover, Verguet Patrick B, CVP, Europe sold 92 shares of the stock in a reserved transaction that ensued on 8/23/2016. At a price of $117.16, the stock was sold for an entire value of $10,779. Consequent to the transaction Verguet Patrick B owned a total of 138,906 shares of the stock.

Currently, 0.30% shares of Edwards Lifesciences Corp (NYSE:EW) are owned by insiders with -45.67% six-month change in the insider ownership. Mussallem Michael A          is one of the major insider shareholder of the company’s stock, the insider owns 30,638 shares reported on Aug 11, 2016. Cardis John T      is second leading insider shareholder, as of May 13, 2016 the insider owns 98,399 shares of the stock. Verguet Patrick B is another major insider shareholder of the stock, as per record date of Aug 24, 2016 insider owns 128,906shares of the stock.

Edwards Lifesciences Corp (NYSE:EW) ended last trading session at the price of $114.30 whereas a number of traders indicating mean target price will hit $123.95 over the next twelve months, mean value of price target most recently revised on 08/19/16. Edwards Lifesciences Corp (NYSE:EW)’s highest estimates of price target are $140.00 and low forecast is $94.00 based on the opinion of 20 analysts. The price target estimates represents a standard deviation of 10.13. However brokerage recommendations suggests an ABR of 1.53 based on calls of 16 experts, where 11 brokers polls the stock a Strong Buy, 1 suggest the stock a Buy, 4 suggest Hold, 0 are rating the stock as Sell while 0 as Strong Sell.

Edwards Lifesciences Corp (NYSE:EW) is expected to release the earnings of its current quarter on 10/24/16. The company is expected to release $0.68 EPS during current quarter according to 24 analysts whereas the company reported $0.54 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $0.64 and high estimate of $0.54. Edwards Lifesciences Corp (NYSE:EW)’s average revenue estimates for the current quarter are 746.62M according to 22 number of analysts. However its lowest revenue estimates are 721.6M and highest revenue estimates are 762M. A year ago the company’s sales were 616.7M. Its yearly sales growth estimates are 21.10%.

Trader’s Buzzer: Great Basin Scientific Inc (NASDAQ:GBSN), Edwards Lifesciences Corp (NYSE:EW)

Great Basin Scientific Inc (NASDAQ:GBSN) went down -1.50% or -0.003 points to reach at $0.203 during the course of previous trade. The stock traded in the range of $0.20 – $0.23 during its most recent trading session. The stock has total market worth of $8.62M and it has total of 43.12M outstanding shares. Relative strength index (RSI-14) for Great Basin Scientific Inc (NASDAQ:GBSN) is at 20.44.

Historically the stock has slipped -13.62% in the past week and plunged -77.44% in the last four weeks, the stock illustrate that its three months performance stands at -91.17% while its year to date performance is at -99.38%. Stock’s price oscillated from $0.18 to $4,136.87 during past twelve months. The stock is now trading at a distance of -48.42% from SMA-20. The stock is presently trading -81.45% below from its SMA-50. In the current trading session, the stock’s price moved -99.45% below from its SMA-200. If we take a look on its volatility, 20.66 percent was seen in a week and for the month it was 25.02 percent.

Great Basin Scientific Inc (NASDAQ:GBSN) on August 11, 2016 reported financial results for the second quarter ended June 30, 2016.

Second Quarter 2016 Financial Results and Business Highlights

  • Revenue increased 38.7% to $728,957 compared with a year ago
  • Total installed customer base up 126.1% over last year to 260
  • Assay adoption rate (assays placed) up 18.2% over last year
  • Product line to double in third quarter; initial impact to revenues expected in fourth quarter
  • Closed $6 million public offering of units; secured $75 million convertible note
  • Hired Mike Blitz, vice president of US Sales, to lead expansion of sales activities including the commercial launch of the Company’s Shiga Toxin Direct test and Staph ID/R Blood Culture panel

Great Basin Scientific’s Second Quarter 2016 Results

Great Basin reported total revenues for the second quarter 2016 of $728,957, an increase of 38.7% over revenues of $525,506 for the same period in 2015. Continued growth in customer base and the adoption of Group B Strep assay drove the year-over-year increase.

The Company reported 260 customers in the second quarter 2016, compared with 114 customers a year ago, representing an increase of 126.1%.

Operating expenses were $7.7 million in the second quarter 2016 compared with $4.1 million in the second quarter 2015. Research and development expenses increased $1.6 million over the second quarter 2015 to $3.5 million, primarily due to increased clinical and regulatory activities related to the Bordetella pertussis test and bacteria stool pathogens panel and ongoing pipeline development. Selling and marketing expenses increased $850,351 to $1.8 million in the comparable quarters, reflecting increases in the Company’s sales force, higher commissions and customer acquisition costs. General and administrative expenses increased $1.2 million over the second quarter 2015 to $2.5 million in the comparable quarter 2016, primarily due to higher legal, accounting and consulting fees and the costs associated with the hiring of additional accounting and human resources personnel.

Edwards Lifesciences Corp (NYSE:EW) rose 2.72% or +3.13 points in order to take the company’s stock at the price of $118.07 during previous trading session. Stock’s price oscillated between $114.94 and $118.26 for intra-day trading. Relative strength index (RSI-14) for Edwards Lifesciences Corp (NYSE:EW) is at 73.99. It has total market capitalization of $25.82B.

Historically the stock has climbed 3.93% in the past week and soared 11.11% in the last four weeks, the stock illustrate that its three months performance stands at 19.13% while its year to date performance is at 36.32%. The stock hit the peak price level of one year at $118.26 and touched the minimum level of $62.53. The stock is now trading at a distance of 4.84% from SMA-20. The stock is presently trading 11.48% above from its SMA-50. In the current trading session, the stock’s price moved 26.97% above from its SMA-200. The company has a Return on Assets of 13.30%. The company currently has a Return on Equity of 21.80% and a Return on Investment of 15.90%.

Edwards Lifesciences Corp (NYSE:EW) on August 18, 2016 announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis who have been determined by a Heart Team to be at intermediate risk for open-heart surgery. The SAPIEN 3 valve is the first transcatheter aortic valve replacement (TAVR) therapy to obtain this indication in the United States.

Thourani is the co-principal investigator of the SAPIEN 3 valve study.

“The intermediate-risk approval of the SAPIEN 3 valve is a major milestone, since it provides a less-invasive therapy that has demonstrated better outcomes for aortic valve patients, and is supported by the largest and rigorous comparative body of evidence for the treatment of aortic stenosis,” said Larry L. Wood, Edwards’ corporate vice president, transcatheter heart valves.

The SAPIEN 3 valve intermediate-risk approval was based on data from a cohort of the PARTNER II Trial, which studied 2,005 intermediate-risk patients at 51 sites in the United States and Canada. The study demonstrated that patients treated with the SAPIEN 3 valve experienced clinically significant improvements for the composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation at one year as compared to those treated with surgery.  The data were presented in April at the American College of Cardiology’s 65th Annual Scientific Session and simultaneously published in The Lancet.

The expanded intermediate-risk indication granted by the FDA enables Heart Teams to treat patients with the SAPIEN 3 valve who they determine to have a predicted risk of surgical mortality of greater than or equal to 3 percent at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator.

Stock Estimates Under Consideration: Edwards Lifesciences Corp (NYSE:EW)

Edwards Lifesciences Corp (NYSE:EW) plunged -0.30% or -0.32 points during previous trade after opening at the price of $106.51, a total of 1.26M shares exchanged hands compared with its average trading volume of 1.55M shares. The stock has a market capitalization of $22.59B and it has 211.76M outstanding shares.

According to consensus agreement of 24 analysts Edwards Lifesciences Corp (NYSE:EW) will report earnings per share of $0.7 in their quarterly report and it is expected to announce the company’s results on 7/26/2016 AMC. For the current quarter the company has highest EPS estimates of $0.72 and low forecast is $0.68. However a year ago for the same quarter the company has reported $0.57 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.66 while the company reported $0.71 EPS on 4/26/2016 AMC with a difference of 0.05 marking a surprise factor of 7.58%.

Previously for the quarter ended on 12/2015, Edwards Lifesciences Corp (NYSE:EW)’s expected mean EPS was $0.59, the company reported its quarterly earnings per share of $0.63 on 2/2/2016 AMC, beating the analysts’ consensus estimate by 0.04 with surprise factor of 6.78%.

Edwards Lifesciences Corp (NYSE:EW)’s mean EPS estimate was $0.49 for the quarter ended on 9/2015, while it reported EPS of $0.54 on 10/26/2015 AMC, beating the analysts’ consensus estimate by 0.05 with surprise factor of 10.20%.

Back on 7/28/2015 the company’s estimated EPS value was $0.52 and it reported $0.57 earnings per share (EPS) for the quarter ended on 6/2015. The company posted a positive surprise factor of 9.62% by 0.05.

Average EPS forecast for the current year is $2.76 according to 23 analysts making projections for Edwards Lifesciences Corp (NYSE:EW). The most expectant earnings per share estimate of the stock is set at $2.9 while the conservative estimates kept at $2.71 over the current year. Having a look at the historical EPS report, the company attained $2.29 EPS for the previous year. While revenue estimates for the current year is 2.89B, setting the highest revenues estimates of 2.95B and indicating lowest revenues at 2.84B according to agreement of 24 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 724.26M covering forecast of 22 analysts. The company indicates a peak revenue level of 737.15 and 713.7M at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of 22.80% whereas for next quarter it has 18.50% estimations over growth. Its forecasts over growth are 20.50% during current year while analysts’ growth estimation for the next year is 18.80%. Past 5 years growth of Edwards Lifesciences Corp (NYSE:EW) observed at 22.74%, and for the next five years the analysts that follow this company are expecting its growth at 16.85%.

Edwards Lifesciences Corp (NYSE:EW) reached at $106.20 price level during last trade its distance from 20 days simple moving average is 3.09%, and its distance from 50 days simple moving average is 4.90% while it has a distance of 18.76% from the 200 days simple moving average. On year trading price range hit the peak level of $112.00 and touched the lowest level of $62.53 and its distance from 52 week high is -5.04% and current price is above +70.08% from 52 week low.